Publications

Categories
Search
Preclinical
April 17, 2023
AACR
PROTECT™, A Novel Trispecific Antibody Masking Platform With Integrated Immune Modulation Displays Unique Activity and Differentiated Modes of Action
Von Rossum et al.
Preclinical
April 17, 2023
AACR
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
Barnscher et al.
ZW191
March 15, 2023 - March 16, 2023
World ADC London
ZW191: A Potential Best-in-Class TOPO1i ADC for Treatment of FRα-Expressing Solid Tumors
Sam Lawn
Zanidatamab
March 13, 2023
Nature Communications
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Weisser et al.
Preclinical
February 22, 2023 - February 23, 2023
European Bispecific & Multispecific Antibody Congress
Design and Functional Characterization of Zanidatamab Zovodotin (ZW49), a HER2-targeting Biparatopic Antibody Drug Conjugate in Clinical Development​
Stuart Barnscher
Zanidatamab
January 19, 2023 - January 21, 2023
ASCO GI
Zanidatamab + Chemotherapy as First line Treatment for HER2 expressing Metastatic Gastroesophageal Adenocarcinoma (mGEA)
Elimova et al.
Zanidatamab
December 6, 2022 - December 10, 2022
SABCS
Antitumor Activity of Zanidatamab with Palbociclib and Fulvestrant in HER2+ Hormone-Receptor Positive (HR+) Metastatic Breast Cancer
Escrivá-de-Romani et al.
Preclinical
December 5, 2022
Antibody Engineering & Therapeutics Conference
Novel IgG1 Cysteine Insertion Sites Enable Site-Specific Conjugation and Precise Control of Drug to Antibody Ratio
Das et al.
Zanidatamab
December 1, 2022
Lancet Oncology
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Meric-Bernstam et al.
Preclinical
November 10, 2022
SITC
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
October 13, 2022
Cancer Cell
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Colombo et al.
Clinical
September 12, 2022
ESMO
Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers
Jhaveri et al.